Sun Pharma Q3 results: Net profit rises 11% to Rs 2,058.8 crore

In Q3, the revenue from specialty products came in at $183 million, up 21 per cent YoY

The country’s largest pharma player, Sun Pharmaceutical Industries, which has an 8.2 per cent share of the Rs 1.67 trillion Indian market, posted an 11 per cent year-on-year (YoY) rise in consolidated revenues to Rs 9,814.2 crore in Q3FY22, riding on strong growth in its key markets – India and the US.

The net profit for the quarter was Rs 2,058.8 crore. The Ebitda came in at Rs 2,557.4 crore, with a resulting Ebitda margin of 26.1 per cent. The board also declared an interim dividend of Rs 7 per share. The stock ended 0.8 per cent